Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.47 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123035 | 1.00 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913635 | 1.00 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3118682 | 0.88 | CACNA2D1 (0.49) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL6901313 | 0.88 | CACNA2D1 (0.49) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913607 | 0.88 | CACNA2D1 (0.49) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3123234 | 0.87 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3120939 | 0.87 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913782 | 0.87 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3112431 | 0.87 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3121915 | 0.86 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | claimed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | claimed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | claimed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | claimed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | claimed |
| US-20170196908-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY | 2017-07-13 | — | — | US | claimed |
| EP-3151818-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | Case Western Reserve University (US) | 2017-04-12 | — | — | EP | claimed |
| WO-2015187942-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-12-10 | — | — | WO | claimed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | claimed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | claimed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | claimed |
| EP-2509596-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | Case Western Reserve University (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071995-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-06-16 | — | — | WO | claimed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| EP-2509596-B1 | GAMMA AMINOACIDS FOR TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2509596-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | Case Western Reserve University (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071995-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | CACNA2D1 3541/4885CACNB3 1477/4885CACNA1C 2966/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | CACNA2D1 3713/4885CACNB3 1205/4885CACNA1C 2214/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | CACNA2D1 3713/4885CACNB3 1205/4885CACNA1C 2214/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | CACNA2D1 3541/4885CACNB3 1477/4885CACNA1C 2966/4885 |
| US-20170196908-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | CACNA2D1 3713/4885CACNB3 1205/4885CACNA1C 2214/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | CACNA2D1 4464/4885CACNB3 2558/4885CACNA1C 3394/4885 |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | CACNA2D1 4464/4885CACNB3 2558/4885CACNA1C 3394/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | CACNA2D1 3713/4885CACNB3 1205/4885CACNA1C 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.